Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark O'Reilly

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Lancet (London, England)|February 28, 2026
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trialChloe Orkin, Peter J Ruane, Malcolm Hedgcock, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 3, 2020
Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up TrialJoseph S Doyle, Daniela K van Santen, David Iser, et al.
The Lancet. HIV|May 9, 2026
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trialEric G Meissner, Moti Ramgopal, Peter J Ruane, et al.
The New England Journal of Medicine|July 8, 2026
Meningococcal B Vaccine to Prevent <i>Neisseria gonorrhoeae</i> InfectionKate L Seib, Basil Donovan, Fengyi Jin, et al.
The Lancet. HIV|August 7, 2025
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi processChloe Orkin, Amy Paterson, Alexa Elias, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Lancet (London, England)|February 28, 2026
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trialChloe Orkin, Peter J Ruane, Malcolm Hedgcock, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 3, 2020
Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up TrialJoseph S Doyle, Daniela K van Santen, David Iser, et al.
The Lancet. HIV|May 9, 2026
Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trialEric G Meissner, Moti Ramgopal, Peter J Ruane, et al.
The New England Journal of Medicine|July 8, 2026
Meningococcal B Vaccine to Prevent <i>Neisseria gonorrhoeae</i> InfectionKate L Seib, Basil Donovan, Fengyi Jin, et al.
The Lancet. HIV|August 7, 2025
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi processChloe Orkin, Amy Paterson, Alexa Elias, et al.
Pageof 8